GLP-1 drugs beat metformin on outcomes in people with prediabetes and obesity, AHA data suggest
_Image credit: MIMS_
MIMS's autumn research round-up highlights a retrospective study of about 129,000 matched pairs presented at the American Heart Association meeting: more people on GLP-1s returned to normal blood sugar than on metformin (37.3% versus 29.3%), and fewer progressed to type 2 diabetes (25.1% versus 37%). GLP-1 use was also linked to lower all-cause death and heart failure risk, though the design cannot prove cause.
Source: MIMS (9 Nov 2026). Image: MIMS.